Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
More from Business
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.
• By
Enzene Biosciences is likely to front-load capacity at its new US facility amid an onshoring focus, CEO Himanshu Gadgil tells Scrip. Possible US tariff exemption for Indian pharma products, impact of higher steel and aluminum tariffs on US manufacturing and a change in the company’s biosimilars strategy are discussed in this wide-ranging interview.
• By
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.